TABLE 5.
Comparative characteristics of the studied groups in terms of CADSS scores measured before the ketamine infusions.
| TRD-MDD-P (n = 17) |
TRD-BD-P (n = 18) |
P-value | |
| I infusion | 0.08921 | ||
| SD | 1.2 (3.3) | 0.4 (1.6) | |
| Range | 0.0–14.0 | 0.0–7.0 | |
| Median (IQR) | 0.0 (1.0) | 0.0 (0.0) | |
| 95% CI | [−0.5; 2.9] | [−0.4; 1.2] | |
| II infusion | 0.38181 | ||
| SD | 0.3 (0.7) | 0.0 (0.0) | |
| Range | 0.0–2.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [−0.1; 0.6] | [0.0; 0.0] | |
| III infusion | 0.26891 | ||
| SD | 0.3 (0.5) | 0.2 (0.7) | |
| Range | 0.0–1.0 | 0.0–3.0 | |
| Median (IQR) | 0.0 (1.0) | 0.0 (0.0) | |
| 95% CI | [0.1; 0.5] | [−0.2; 0.5] | |
| IV infusion | 0.56351 | ||
| SD | 0.1 (0.3) | 0.0 (0.0) | |
| Range | 0.0–1.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [−0.1; 0.3] | [0.0; 0.0] | |
| V infusion | 0.38181 | ||
| SD | 0.2 (0.4) | 0.0 (0.0) | |
| Range | 0.0–1.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [0.0; 0.4] | [0.0; 0.0] | |
| VI infusion | 0.75391 | ||
| SD | 0.2 (0.4) | 0.1 (0.3) | |
| Range | 0.0–1.0 | 0.0–1.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [0.0; 0.4] | [0.0; 0.3] | |
| VII infusion | 0.56351 | ||
| SD | 0.1 (0.3) | 0.0 (0.0) | |
| Range | 0.0–1.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [−0.1; 0.3] | [0.0; 0.0] | |
| Follow-up | 0.38181 | ||
| SD | 0.2 (0.6) | 0.0 (0.0) | |
| Range | 0.0–2.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [−0.1; 0.5] | [0.0; 0.0] |
1U Mann-Whitney; SD, standard deviation; IQR, interquartile range; TRD-MDD-P, treatment resistant major psychotic depression; TRD-BD-P, treatment resistant bipolar psychotic depression; CADSS, Clinican Administered Dissociative States Scale.